We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesHarvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc.

Consumer Defensive Packaged Foods
PortfolioPortfolio WatchlistWatchlist
Company price
1.81 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
4920
Market Cap
46.65M

Momentum Score

…

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.81
Low
2.01
High
52 Week Price Range
0.96
Low
2.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Harvard Apparatus Regenerative Technology Inc. is an OTCQB-listed company that identifies itself as developing regenerative medicine technologies; public information about the company is limited. Major long-term growth drivers could include broader adoption of regenerative therapies and successful translation of its technologies into commercial products or licensing arrangements. Investors may find exposure to the regenerative-medicine sector attractive if the company advances development or secures partnerships that reduce commercialization risk.

Principal investment risks include early-stage and unproven technology with substantial clinical and regulatory hurdles, likely need for external financing and shareholder dilution, and thin OTC trading liquidity that could increase price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.81
Dividend Yield
-
Revenue TTM
0.98M
Revenue Per Share
0.06
Gross Profit TTM
0.07M
Debt / Equity
-
ROE
-636.54%
Net Debt
-
ROCE
-604.99%
Diluted EPS TTM
-0.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.87M -7.73M -8.95M -6.07M -7.98M
Net income -6.87M -7.73M -8.95M -6.07M -7.98M
Selling general administrative 4.32M 5.58M 6.01M 4.41M 7.04M
Gross profit 0.06M 0.16M 0.08M 0.00M -
Reconciled depreciation 0.10M 0.17M 0.13M 0.05M 0.11M
Ebit - - - - -8.64M
Ebitda - - - -6.10M -8.47M
Operating income -6.92M -7.73M -8.99M -6.15M -8.47M
Interest expense 0.01M 0.04M 0.01M - -
Interest income 0.04M 0.03M 0.06M - -
Net interest income 0.03M -0.01M 0.05M - -
Total revenue 0.70M 0.43M 0.10M 0.00M 0.00M
Total operating expenses 7.62M 8.16M 9.09M 6.15M 8.47M
Cost of revenue 0.65M 0.27M 0.02M - -
Total other income expense net 0.02M - -0.01M 0.08M 0.49M
Net income from continuing ops -6.87M -7.73M -8.95M -6.07M -7.98M
Net income applicable to common shares - - - - -7.98M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.68M 4.44M 2.61M 2.40M 1.87M
Other current assets 0.19M 0.26M 0.01M 0.05M 0.06M
Total liab 1.62M 1.22M 0.97M 1.41M 4.89M
Total stockholder equity 1.06M 3.22M 1.65M 0.99M -3.03M
Other current liab - - 0.00M 0.01M 3.25M
Common stock - - - - 0.11M
Capital stock 0.18M 0.16M 0.14M 4.30M 0.11M
Retained earnings -106.56M -99.69M -91.96M -83.01M -76.94M
Cash 1.35M 2.49M 0.43M 1.24M 1.24M
Total current liabilities 1.53M 1.02M 0.97M 1.36M 4.84M
Property plant equipment - - - - 0.28M
Total current assets 1.83M 3.23M 0.78M 1.59M 1.59M
Net tangible assets - - - - -3.03M
Net receivables 0.02M 0.23M 0.00M - -
Inventory 0.02M 0.08M 0.05M - -
Accounts payable 0.45M 0.45M 0.45M 0.68M 0.68M
Non currrent assets other - - - - 0.57M
Non current assets total 0.85M 1.21M 1.83M 0.81M 0.57M
Capital lease obligations 0.20M 0.29M 0.05M 0.15M 0.17M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M -0.01M 0.00M
Change to liabilities - - - 0.00M 0.65M
Net borrowings 0.00M 0.00M 0.00M - -
Total cash from financing activities 2.70M 6.91M 6.14M 5.06M 2.84M
Change to operating activities - - - - 4.04M
Net income -6.87M -7.73M -8.95M -6.07M -7.98M
Change in cash -1.13M 2.05M -0.81M -0.05M 0.22M
Begin period cash flow 2.49M 0.43M 1.24M 1.29M 1.08M
End period cash flow 1.35M 2.49M 0.43M 1.24M 1.29M
Total cash from operating activities -3.83M -4.85M -6.94M -5.11M -2.63M
Issuance of capital stock 2.70M 6.48M 5.99M 5.06M 2.84M
Depreciation 0.10M 0.17M 0.13M 0.05M 0.11M
Change to inventory 0.06M -0.03M -0.05M - -
Change to account receivables 0.21M -0.23M -0.00M - -
Sale purchase of stock - - - - 0.00M
Change to netincome - - - 0.42M 0.56M
Capital expenditures 0.00M 0.00M 0.01M 0.01M 0.00M
Change in working capital 0.93M 0.31M -1.59M -0.11M 4.69M
Stock based compensation 2.01M 2.40M 3.46M 1.03M 0.98M
Free cash flow -3.83M -4.85M -6.95M -5.11M -2.63M

Peer Comparison*

Sector: Consumer Defensive Industry: Packaged Foods

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HRGN
Harvard Apparatus Regenerative Technology Inc.		 -
-%		 1.81 - - 47.51 267.53 35.39 -7.27
NSRGF
Nestle SA		 -
-%		 101.69 26.86 18.76 3.13 7.10 3.81 21.70
NSRGY
Nestle SA ADR		 0.07
0.07%		 103.51 26.82 18.66 3.18 7.07 3.81 21.70
DANOY
Danone PK		 0.23
1.52%		 15.40 24.23 17.64 1.88 2.57 1.88 11.70
GPDNF
Danone S.A		 -
-%		 75.00 20.30 14.75 1.65 2.24 1.76 10.92

Profile*

Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

84 October Hill Road, Holliston, MA, United States, 01746

774 233 7300

https://hregen.com

8

Name Title Year Born
Mr. Junli He C.F.A. CEO & Chairman 1974
Mr. Yu Hong B.S., C.F.A., M.S. President 1973
Mr. Joseph L. Damasio Jr. Chief Financial Officer 1974
Dr. William L. Fodor Ph.D. Chief Scientific Officer 1959
Dr. Shunfu Hu Ph.D. Corporate Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…